Physician profile
Prasun Pushkarray Shah
NPI 1720575293
$6,790.99
in general payments reported to CMS, 2019-2025
30 companies · $1,913 in 2025
The $1,913 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.56 · 2020: $102 · 2021: $644 · 2022: $1,004 · 2023: $1,528 · 2024: $1,561 · 2025: $1,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,001.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,311.12 | 2020-2025 | Linzess, Viberzi, Mavyret |
| Gilead Sciences, INC. | $559.43 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $551.76 | 2020-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $428.83 | 2020-2025 | Trulance, Xifaxan |
| Qol Medical, LLC | $299.75 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $284.89 | 2022-2024 | Zeposia |
| Redhill Biopharma INC. | $272.26 | 2021-2025 | Talicia |
| Phathom Pharmaceuticals, INC. | $249.85 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $201.45 | 2022-2023 | Zeposia |
| Conmed Corporation | $175.73 | 2020-2025 | Conmed Generators, Conmed Biliary |
| Ironwood Pharmaceuticals, INC | $166.66 | 2022-2024 | Linzess |
| Boston Scientific Corporation | $159.53 | 2021-2023 | Spyglass |
| Janssen Biotech, INC. | $158.88 | 2022-2025 | Stelara, Tremfya |
| Nestle Healthcare Nutrition INC. | $157.97 | 2022-2023 | |
| Genzyme Corporation | $131.88 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $116.43 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $112.34 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $66.75 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $59.67 | 2025 | Omvoh |
| Vivus LLC | $56.96 | 2025 | Pancreaze |
| Echosens North America, INC. | $56.64 | 2025 | Fibroscan |
| Regeneron Healthcare Solutions, INC. | $38.42 | 2025 | Dupixent |
| Romark Laboratories, Lc | $28.15 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $26.54 | 2025 | Iqirvo |
| Erbe USA INC | $25.45 | 2021 | |
| Braintree Laboratories, INC. | $21.59 | 2023 | Sutab |
| Alcresta Therapeutics, INC. | $20.37 | 2024 | Relizorb |
| Novo Nordisk INC | $18.13 | 2025 | Wegovy |
| Evoke Pharma, INC. | $17.04 | 2023 | Gimoti |
| Intercept Pharmaceuticals, INC. | $16.52 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasun Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.